Cargando…

Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis

OBJECTIVE: To evaluate the efficacy and safety of thrombopoietin receptor agonists (TPO-RAs) in solid tumors with chemotherapy-induced thrombocytopenia (CIT). METHODS: We conducted a comprehensive search of PubMed, FMRS, Cochrane Library, Web of Science, EMBASE, and ClinicalTrials.gov for randomized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Wen, Liu, Yubingxue, Li, Luchun, Zeng, Xianghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693054/ https://www.ncbi.nlm.nih.gov/pubmed/38041150 http://dx.doi.org/10.1186/s40360-023-00707-5

Ejemplares similares

Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia
por: Shin, Jiwon, et al.
Publicado: (2023)

Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis
por: Guo, Jian-Chun, et al.
Publicado: (2017)

Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia
por: Bastida, José María, et al.
Publicado: (2021)

Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis
por: Wang, Li, et al.
Publicado: (2016)

Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia
por: Garzon, Angelica Maria, et al.
Publicado: (2015)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists
por: Nilles, Kathy M., et al.
Publicado: (2019)

Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
por: González-Porras, José R., et al.
Publicado: (2019)

Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial
por: Deng, Junzhu, et al.
Publicado: (2021)

Thrombopoietin Receptor Agonists: Can These Be the Future Answer to the Deadly Thrombocytopenia in Dengue Fever?
por: Roy, Sayak
Publicado: (2019)

Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review
por: Agarwal, Nikki, et al.
Publicado: (2021)

Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
por: Drillet, Gaëlle, et al.
Publicado: (2022)

P1666: EFFECT OF AGONISTS TO THROMBOPOIETIN RECEPTORS ON PLATELET GLYCOME OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Monzón Manzano, E., et al.
Publicado: (2022)

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
por: Rainone, Michael, et al.
Publicado: (2023)

Successful Treatment with Thrombopoietin Receptor Agonist in Avoiding Splenectomy for Patients with Chronic Refractory Immune Thrombocytopenia
por: Khalafallah, Alhossain, et al.
Publicado: (2012)

Efficacy and Safety of Recombinant Human Thrombopoietin on Sepsis Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis
por: Zhang, Jin, et al.
Publicado: (2020)

Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag
por: Abdela, Jemal
Publicado: (2019)

Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations
por: Carpenedo, Monica, et al.
Publicado: (2021)

PB2626: THROMBOPOIETIN RECEPTOR AGONISTS FOR RESISTANT THROMBOCYTOPENIA IN PREGNANCY A CASE SERIES AND REVIEW OF LITERATURE
por: Sayed, Gamal, et al.
Publicado: (2023)

Thrombopoietin receptor agonists: ten years later
por: Ghanima, Waleed, et al.
Publicado: (2019)

Effect of Thrombopoietin Receptor Agonist on Pregnant Mice
por: Nakai, Kensaku, et al.
Publicado: (2022)

The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia
por: Wang, Wenxian, et al.
Publicado: (2022)

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
por: Jurczak, Wojciech, et al.
Publicado: (2018)

Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
por: Lozano, Maria L., et al.
Publicado: (2019)

P1635: REAL-WORLD DATA OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) USE IN IMMUNE THROMBOCYTOPENIA (ITP)
por: Dangudubiyyam, S., et al.
Publicado: (2022)

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus
por: Pulanić, Dražen, et al.
Publicado: (2023)

PB2618: USE AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE CENTRE EXPERIENCE
por: Martinez, Celia, et al.
Publicado: (2023)

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
por: Mei, Heng, et al.
Publicado: (2021)

Retracted: The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Safety of non‑peptide thrombopoietin receptor agonists in patients with immune thrombocytopenia: A systematic review and meta‑analysis of short‑term double‑blind randomized clinical trials
por: Shen, Nan, et al.
Publicado: (2023)

The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence
por: Qureshi, Kamran, et al.
Publicado: (2016)

Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report
por: Baur, Rebecca, et al.
Publicado: (2021)

P1636: PATIENT PREFERENCES AND EXPERIENCES REGARDING THROMBOPOIETIN-RECEPTOR AGONISTS FOR IMMUNE THROMBOCYTOPENIA IN THE NETHERLANDS (TRAPEZE NL STUDY).
por: Jansen, A. G., et al.
Publicado: (2022)

Cerebral venous sinus thrombosis in immune thrombocytopenia patients treated with thrombopoietin receptor agonist: Case reports and literature review
por: Teekaput, Chutithep, et al.
Publicado: (2022)

The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity
por: Hamed, Eman Mostafa, et al.
Publicado: (2023)

P1629: DISCONTINUATION OF TREATMENT WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE-CENTER CLINICAL EXPERIENCE
por: Santano, Ana María Mena, et al.
Publicado: (2023)

Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy
por: Napolitano, Mariasanta, et al.
Publicado: (2023)

Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method
por: Cuker, Adam, et al.
Publicado: (2020)

Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
por: Lozano, Maria L., et al.
Publicado: (2021)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
por: Pecci, Alessandro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_iilfsnuovuk7q5b7qtpp2kqh3n